South Korea FDA Warns Again About GSK's Avandia Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
South Korea's FDA issued another warning advising heart patients about GlaxoSmithKline's Avandia (rosiglitazone) for treating diabetes